afternoon. Genomics results. joining for XXXX fourth this earning and our everyone I'm review to to to quarter you thank us and Kerry, call welcome pleased Thanks, you XXx year-end
Officer, Brad will Officer. Chief Commercial is join Chief Joining Justin Q&A. me today our our Financial McAnear us for Crutchfield,
a Then we'll more big our talk to was growth XXx. commercial update XXXX. drive over a on outlook call, pipeline. of financials capabilities I today's provide and XXXX I detailed some our will turn investments look call On to for and through new the for our execution, Justin the about year in future for our will walk an at
revenues up to grow we ended and total with revenue, over the XX% continued year in Our XXXX. $XXX.X million
to rapidly during large The our now of and During year, scientific and publications body papers doubled discoveries over than there our fundamental we scientific also continued XXX coming the are customers have of see out more customers' XXXX labs. number publications a our of growing using made products. where
even been the of being areas And where of are our has we tremendous do applications products of the where a have than more exciting work their our publications number customers and seen number used. breadth
to of approach autoimmune discoveries powerful the to During studies fundamental demonstrated discovery. paper I in the breakthroughs diseases, major are there of in from strikingly to wanted that age-related from, choose studies Alzheimer's, And many work year, have a on great we important many quarter seen diseases. types cancers, while last highlight fascinating antibody
our University understanding Researchers to solution patients and immune screen HIV-infected exquisite profiling their from of an out influenza-specific Vanderbilt vast quickly HIV while of gaining to cells antibodies, numbers use specificities. of B find
the for the the new was and to will tools lead new cures. shows century It and will performing be huge motivator These technologies, of a biology. understanding therapeutic how areas. become We development this of we work demonstrates kind why a antibody and This integral discovery for this approach for wide vaccine customers will expect that of across our an by range is tool into studies with new team. work XXx believe
turning commercial execution. Now to
customers With enables samples in September we We to platform platforms: began level spatial Visium instrument, require Chromium, will resolution. analysis. and cells Visium to started The which November. each are Visium what see able at in products not are end our Visium, unlike platform. and single other shipments Chromium how with arranged The preorders able molecules an of two happening, it resolution, tissues. and at does customers single Chromium Chromium believe the that happening where is adoption enables in And With accelerate their Visium. to respect is core the right the around for of all this Our cell remember organized are see taking cell platform analysis. our of
very and potential. early interest excited our Even is customers seeing days, though We're it about the initial product this expectations. we're exceeded new from its have
used Visium was of as fact labs. In than more the by year-end already being XXX
our While customers of of demonstrated by Visium products be and function of we're trajectory early interest, adoption the their success. use this excited will a these how
So across we far different have seen interest Visium, with many research areas.
interest our in more among Visium has in translational initial been notably particular focus discovery, oncology most on applications seen in and While has Alzheimer's.
to Our customers responses look in to samples, therapy. biomarkers disease are predict study patient Visium for using and
the platform launch was this Visium last the but Gene measuring the The first first for just at year product. is of end on product Expression,
many have obligations to enable platform. and analytes biological to the make underlying We measure additional more works to in new to the improvements
all GEM point continues architecture we instruments solutions. Now At operate GEM progress looking with Chromium Next Next platform, this to sell well. to the at our Chromium exclusively that our transition
using be We our end products existing by studies our complete have customers not disrupt and the GEM of year. the expect been to the legacy of careful transition to
sold Chromium Across have year-end our in the two our platforms; instruments core pull-through cumulative customers And of around over we world. revenue of Visium of XXXX. X,XXX $XXX,XXX Chromium annual a a averaged and consumable as
our invest to in usage the for will number products new efforts customers the both increase we of customers. to existing increase our of forward and Going
the tremendous ahead focused of on business and scaling we a for are see our road opportunities future. We
products and One pillars rapid velocity. of of at to what ability build our competitive them advantage build the innovation comprises which our core the engine breakthrough knowing is both to
impact. roadmap long R&D. identified executing in exciting we're and biggest advantage these that of product in opportunities our opportunities are have exponential term The the a have near potential on rich many increasing for investment We and
is some team discuss of growth. on substantially I programs long-term a Our and working add all which which of our today will of number can to
over patents single including analysis, cell patents have we analysis cell spatial As epigenomics, issued now or and our innovations to genomics, relating XXX the in pioneer foundational multigenomics. pending of key single
also continue to in investing this invest in patent to and operational our production. We infrastructure provides growth. and our defending heavily which rapid We're significant portfolio developing support differentiation
We system and a are support expansion to manufacturing Singapore operations. of transitioning continuity after to ERP our actively global new out this year. also ensure the site to a the building We're global
Our working commercial We employees Pacific approach organization distribution ended Asia Europe XXXX with sales to direct hybrid America North executives. employees sold develop with and a over XXX individual over local in XXx commission with partners together XX in markets. and employ and
new complements direct our our innovation questions. infrastructure with their through and of close rapid adoption And global their product This future to for our products an information into directly our allows pipeline. and commercial into us to products. experience deliver feeds Our It needs products. to our innovate identify partnership to development engine we both customer future have insight opportunities ever-improving drive rapidly customers
epigenetic epigenetic is next launch directly to which And going customers cells. starting The Gene epigenetics now some gene to capabilities same our output Chromium programming With we're been And we on product. from together to precisely read biggest the cell. programming working with will our be with platform. our our that capabilities, the our of able expression have have But to request received from able the across Expression. is large its single linking next challenge measure the capability and is preview of the I numbers we're to customers is existing
the able R&D read using -- thousands thousands epoxy epigenetic very single gene first in a across of will For to tens be expression customers both of our of programming time cells and experiment.
fundamental unlocking to interested the human Our it start capability most them will with because and programming and of allow intently customers addressing this the it to have challenges in of health cellular disease. been rules one
second one of focus to of platform. the offshoring make our the for revolution products to The biologists. further the single Since cell core tenets is reach Chromium our innovation accessible in broaden all to of is
thousands that expensive the two While researchers is research flexible. and enable technology. for that next labs the And by cell make way our be to be we world, across transforming more goal to of single starting has is approach capabilities of around tens will single of cell this intrigued science this thousands been new are who end, less experiments just to to new launching done
full means overall of single of customers This to sequencing the our subset enable genes. cost will sequencing. cost the cell, each targeted a of we of now cell just reduce sequence dramatically able First, the This will be transcriptome will decreased that sequencing experiments. incentive significantly and
what customers practical. will be increase the be of cell launching and to validation is into also We're our experiments more samples combine more allow that This available XXx opening to number It to allow focused samples specific scaled lane. up analysis for single together cases. experiments single on will a and currently allow beyond proprietary will solutions use questions also translational
allows platform cell routinely. further experiments to is launch And third single for finally, time XX,XXX for experiments. this to of helped beyond. to Chromium scale experiments labs that area XXXX and cell have the of X,XXX run The cell focus of our we first customers point, throughput the increase Since in
is In fact the way experiments scale. actually complex through running biology is labs very complexity many XXX,XXX address But are routinely. and cell to now this
We This and drug expect experiments. to customers transform many analysis, features like will new analysis we the launching enormous where next experiments. the single This we scale parallel is two scale. this our going in type resolution million pathology point And research large-scale we and be within the interest future cell enable [ph] will the population our million have enable cell years over cohort where beyond at running sites. of an now capabilities cell will technology gene develop used. single well of of products multiple heard amount and experiments cells, scale could across XX from one And in massively enable to applications of fact areas millions screens currently to also
now Visium. to Turning
of license pathologists to their workloads. immunonhistochemistry, of tissues analysis way or Visium, high which fluorescence brought using uses analyze of protein launch markers. the we The tissues throughput and IHC measure molecule standard is With pathology
world of from delivering molecular their a customers our analysis serve even the that new We're same at throughput Visium from as we'll that high now will the we're new sample that from the capability samples. more bridge to a time. from launch will the expression book customers get allow increase the rich to of Visium. the IHC and same But significantly This world can planning pathology same information with traditional amount gene tissue, the the to of our importantly,
IHC is capability featured protein to limitation, technology it we're high This the measuring antibodies. this our where time proteins at address on pushed customers scale using be gene of to very potentially thousands of maybe could featured bar can same With measure be great of be tissues. can levels sample. We fundamental same two, biological customers [indiscernible] to bar one believe our customers to expression point can't much protein will the further. even really with extract and our Visium. technology this To able targets will bringing the hundreds, information for but measuring coding be together transformative kind samples marker coding, from the the
our a great been received has and finally, grounded said, we with deal clinical of translational research. foundational That early and already researchers. And discovery focus from squarely have Visium in interest
these which of important is customers, are to the way the standard formalin-fixed collected pathology. FFP, most type or paraffin-embedded is human samples For sample and patient stored that
fine FFP Now awful sample. but to a things absolutely the visualizing of it is does kinds for tissues, molecules that for in it is
Our current with initially be not designed compatible to Visium was product FFP.
as we amount will given platform we interest, the incredible the product have be capability now to and future. this for However, internally developed with work in the releasing the FFP a of
to on has the been very a We're to new each I'm more capabilities is Genomics. what team AGBT of date. next very very proud XXx has forward of I providing excited eventful these at conference. look the ahead. our progress week for at This year details made
confident to XXXX, $XXX the year range be in of on well-positioned strategy to usher to we we continue we the we of the for coming are in decades Looking the I'm would $XXX revenue as -- our into execute that to ahead XXXX in biology. and to million century full expect million. well
for financials. McAnear detail with more the will over turn now And on call Justin that, I our to
